Bleakley Financial Group LLC Has $4.87 Million Position in Pfizer Inc. $PFE

Bleakley Financial Group LLC raised its position in Pfizer Inc. (NYSE:PFE) by 17.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 173,587 shares of the biopharmaceutical company’s stock after purchasing an additional 25,800 shares during the quarter. Bleakley Financial Group LLC’s holdings in Pfizer were worth $4,874,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. WJ Financial Advisors LLC increased its stake in shares of Pfizer by 4.3% in the first quarter. WJ Financial Advisors LLC now owns 11,123 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 456 shares during the period. Principal Financial Group Inc. raised its holdings in Pfizer by 0.5% in the 1st quarter. Principal Financial Group Inc. now owns 6,339,372 shares of the biopharmaceutical company’s stock valued at $178,010,000 after buying an additional 32,564 shares during the last quarter. Citizens National Bank Trust Department boosted its position in Pfizer by 3.7% during the 1st quarter. Citizens National Bank Trust Department now owns 48,294 shares of the biopharmaceutical company’s stock worth $1,356,000 after buying an additional 1,739 shares during the period. Chicago Partners Investment Group LLC grew its holdings in Pfizer by 13.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 93,273 shares of the biopharmaceutical company’s stock worth $2,500,000 after acquiring an additional 11,016 shares during the last quarter. Finally, Vantage Point Financial LLC grew its holdings in Pfizer by 2.5% during the 1st quarter. Vantage Point Financial LLC now owns 21,256 shares of the biopharmaceutical company’s stock worth $597,000 after acquiring an additional 514 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Morgan Stanley boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Wolfe Research restated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. BMO Capital Markets lowered their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.50.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst coverage remains supportive, even after some modest price-target cuts. BMO kept an outperform rating and Guggenheim maintained a buy, suggesting Wall Street still sees upside from current levels. Benzinga analyst update
• Positive Sentiment: Pfizer’s oncology franchise is in focus ahead of Q2 results, with growth from key cancer drugs, biosimilars, and pipeline updates potentially helping offset declines in older medicines. Zacks oncology outlook
• Positive Sentiment: Investors are also encouraged by the long-term case for Pfizer’s Seagen integration, which some analysts argue could improve oncology growth and create durable value versus peers like Amgen. 247WallSt Pfizer vs. Amgen
• Neutral Sentiment: Pfizer’s dividend yield remains unusually high at about 7.1%, which may attract income investors, but it also raises questions about whether the payout reflects slower growth expectations. Motley Fool dividend article
• Negative Sentiment: Near-term earnings expectations are soft, with Wall Street looking for a double-digit decline in profit in the next quarterly report, reinforcing concerns about pressure on Pfizer’s core business. Barchart earnings preview
• Negative Sentiment: Drug-pricing headlines tied to the Trump administration are adding policy uncertainty across big pharma, including Pfizer, even though pipeline strength may ultimately matter more. Motley Fool drug-pricing article

Pfizer Trading Down 1.0%

PFE opened at $24.24 on Wednesday. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The company has a fifty day moving average of $25.28 and a 200-day moving average of $26.18. The stock has a market cap of $138.17 billion, a PE ratio of 18.51 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.